Robert W. Baird set a $75.00 price objective on TESARO (NASDAQ:TSRO) in a research note published on Monday. The brokerage currently has a hold rating on the biopharmaceutical company’s stock.
Several other research firms also recently issued reports on TSRO. BidaskClub raised shares of TESARO from a buy rating to a strong-buy rating in a report on Friday, October 19th. Oppenheimer set a $83.00 target price on shares of TESARO and gave the company a buy rating in a research note on Sunday, November 11th. Wells Fargo & Co cut shares of TESARO from an outperform rating to a market perform rating in a research note on Monday. Cowen reiterated a hold rating and set a $38.00 target price on shares of TESARO in a research note on Monday, October 22nd. Finally, Bank of America upped their target price on shares of TESARO from $38.00 to $39.00 and gave the company a neutral rating in a research note on Friday, November 2nd. Fifteen analysts have rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company. The company presently has a consensus rating of Hold and a consensus target price of $78.18.
NASDAQ TSRO opened at $73.78 on Monday. The company has a current ratio of 3.40, a quick ratio of 2.83 and a debt-to-equity ratio of 3.74. TESARO has a 1 year low of $23.41 and a 1 year high of $85.48.
TESARO (NASDAQ:TSRO) last posted its quarterly earnings data on Thursday, November 1st. The biopharmaceutical company reported ($2.49) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($2.62) by $0.13. The business had revenue of $64.40 million during the quarter, compared to the consensus estimate of $71.84 million. TESARO had a negative net margin of 295.67% and a negative return on equity of 1,209.72%. TESARO’s quarterly revenue was down 54.9% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.47) EPS. On average, equities analysts forecast that TESARO will post -10.94 EPS for the current fiscal year.
Several hedge funds have recently made changes to their positions in the company. Great Lakes Advisors LLC acquired a new position in shares of TESARO in the 3rd quarter valued at $4,098,000. Vanguard Group Inc. raised its stake in shares of TESARO by 3.6% in the 3rd quarter. Vanguard Group Inc. now owns 3,336,421 shares of the biopharmaceutical company’s stock valued at $130,154,000 after buying an additional 116,337 shares in the last quarter. TIAA CREF Investment Management LLC raised its stake in shares of TESARO by 27.8% in the 3rd quarter. TIAA CREF Investment Management LLC now owns 1,372,970 shares of the biopharmaceutical company’s stock valued at $53,560,000 after buying an additional 298,457 shares in the last quarter. Teachers Advisors LLC raised its stake in shares of TESARO by 53.5% in the 3rd quarter. Teachers Advisors LLC now owns 1,016,420 shares of the biopharmaceutical company’s stock valued at $39,651,000 after buying an additional 354,177 shares in the last quarter. Finally, Opus Point Partners Management LLC raised its stake in shares of TESARO by 720.0% in the 3rd quarter. Opus Point Partners Management LLC now owns 94,300 shares of the biopharmaceutical company’s stock valued at $3,679,000 after buying an additional 82,800 shares in the last quarter.
Tesaro, Inc, an oncology-focused biopharmaceutical company, identifies, acquires, develops, and commercializes cancer therapeutics and oncology supportive care products in the United States. It offers ZEJULA (niraparib), an orally active and potent poly polymerase inhibitor for the maintenance treatment of women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer; and VARUBI (rolapitant), a neurokinin-1, or NK-1, receptor antagonist for the prevention of chemotherapy induced nausea and vomiting.
Further Reading: What is a Call Option?
Receive News & Ratings for TESARO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO and related companies with MarketBeat.com's FREE daily email newsletter.